Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therape...
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
The quest for efficiency without compromising safety and compliance is paramount. This was the central theme of the panel discussion titled "Reimag...
Industry pioneers Maria Batalha, Kevin J. Bittorf, Matthew Mollan, and John Nadzam took center stage at INTERPHEX 2024 to share their expertise and insight...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Bora Pharmaceuticals Co., Ltd. announced that it has completed the acquisition of Upsher-Smith Laboratories, LLC. (“Upsher-Smith”),...
The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation ca...
SCHOTT Pharma announces plans to solidify its footprint in the United States with the establishment of a cutting-edge facility in Wilson, Nor...
One of the notable achievements in fiscal 2023 was Catalent's robust efforts to mitigate its environmental impact and combat climate ...
Hovione has entered into a license agreement with Dragonfly Technologies, Inc. to offer its customers the breakthrough micellar technology developed by...
After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary perfor...
This strategic acquisition marks a pivotal step towards creating a combined entity with expanded capabilities and a robust service offering that spans from...
Vetter, a globally recognized contract development and manufacturing organization (CDMO), proudly announces the successful market introduction of eight cus...
© 2024 Biopharma Boardroom. All Rights Reserved.
